Susan G Komen  
I've Been Diagnosed With Breast Cancer Someone I Know Was Diagnosed Share Your Story Join Us And Stay Informed Donate To End Breast Cancer
    Home > Research & Grants > Grants Program > Research Grants > Research Grants Awarded > Basic, Clinical and Translation : 2006-2007

    Research Grants Awarded

    2006-2007 Grant Cycle : Research Grants Awarded

    Basic, Clinical and Translation

    Human and Mouse Linked Evaluation of Tumors (HAMLET)
    Matthew Ellis, MB, PhD, FRCP
    Washington University in St. Louis
    Tumor Cell Biology VI
    $300,000


    Project Connect: Enhancing Connections During Breast Cancer
    Annette Stanton, PhD
    The Regents of the University of California, Los Angeles
    Psychosocial and Complementary Treatment Approache
    $227,367


    Cohesion-dependent Mechanisms of Cancer Progression and Aneuploidy
    Robert V. Skibbens, Ph.D
    Lehigh University
    Tumor Cell Biology V
    $257,172


    Cancer Stem Cells and Breast Cancer Recurrence
    Lewis Chodosh, M.D., Ph.D.
    The Trustees of the University of Pennsylvania
    Tumor Cell Biology II
    $300,000


    Early detection of chemotherapy associated cardiotoxicity in women with breast cancer
    William Hundley, MD
    Wake Forest University Health Sciences
    Detection/Diagnosis/Prognosis
    $299,222


    Antibody-NKG2D Ligand Fusion Protein for Breast Cancer Therapy
    Seung-Uon Shin, Ph.D.
    University of Miami School of Medicine
    Detection/Diagnosis/Prognosis
    $300,000


    A novel DNA/peptide based library for breast cancer therapy
    Ben Park, M.D., Ph.D.
    Johns Hopkins University
    Tumor Cell Biology III
    $300,000


    An Integrated Approach to Biomarker Validation in Patients with HER-2 Positive Metastatic Breast Cancer Treated with Rapamycin and Trastuzumab
    Maysa Abu-Khalaf, MD
    Yale University
    Tumor Cell Biology IV
    $300,000


    N'N'Diarylurea Inhibitors of Translation Initiation for Treatment of Breast Cancer
    Huseyin Aktas, D.V.M., Ph.D.
    Harvard Medical School
    Treatment
    $300,000


    A Functional Genomic Approach to Develop More Rational Taxane Combination Therapies for Metastatic Breast Cancer
    David Azorsa, Ph.D.
    The Translational Genomics Research Institute
    Treatment
    $299,999


    Molecular Imaging of Breast Cancer with breast PET/CT
    Ramsey Badawi, Ph.D.
    The Regents of the University of California (University of California Davis)
    Detection/Diagnosis/Prognosis
    $299,954


    Breast Cancer Brachytherapy Using Nanoparticle-Carried Therapeutic Radionuclides
    Ande Bao, PhD
    Univ of Texas Health Science Center at San Antonio
    Treatment
    $282,377


    p16 Mediated supression of hTERT in Breast Cancer
    Alexey Bazarov, Ph.D.
    The Regents of the University of California, San Francisco
    Detection/Diagnosis/Prognosis
    $297,032


    A novel interaction of Focal Adhesion Kinase and p53 in breast cancer cells
    Vita Golubovskaya, Ph.D.
    University of Florida
    Tumor Cell Biology I
    $300,000


    Characterisation of the mammary epithelial cell hierarchy and implications for breast cancer
    Jane Visvader, Ph.D.
    The Walter & Eliza Hall Institute of Medical Research
    Tumor Cell Biology I
    $300,000


    Regulatory T Cells and Breast Cancer Risk
    Kirsten Moysich, Ph.D.
    Roswell Park Cancer Institute Alliance Foundation
    Risk, Prevention and Epidemiology
    $300,000


    The role of apoptosis gene variants in familial breast cancer
    Nicola Camp, Ph.D.
    University of Utah
    Risk, Prevention and Epidemiology
    $300,000


    Novel Regulators of EGFR Signaling in Breast Cancer
    Karl Chai, Ph.D.
    University of Central Florida
    Tumor Cell Biology I
    $300,000


    Telomere dysfunction-induced senescence as a barrier for the development of breast carcinomas
    Sandy Chang, MD, PhD
    University of Texas M.D. Anderson Cancer Center
    Tumor Cell Biology V
    $300,000


    Cell cycle-dependent regulation of human BRCA2 gene expression by SLUG and PRDX5C
    Gautam Chaudhuri, Ph.D.
    Meharry Medical College
    Tumor Cell Biology I
    $300,000


    Genome-wide mapping of MicroRNA binding sites in breast cancer cells and associated fibroblasts
    Izhak Haviv, Ph.D
    The University of Melbourne
    Tumor Cell Biology VI
    $300,000


    A New Mechanism of Breast Cancer Progression
    Henry Heng, Ph.D.
    Wayne State University
    Detection/Diagnosis/Prognosis
    $300,000


    Combined effects of a sulfoxide-containing anticancer prodrug and Herceptin against breast cancer
    Kun-Ming Chen, Ph.D.
    Penn State College of Medicine
    Treatment
    $294,951


    Inhibitors of eIF4E/eIF4G Interaction as Potential Anti-Breast Cancer Drugs
    Michael Chorev, Ph.D.
    Harvard Medical School
    Treatment
    $300,000


    Role of Cyr61(CCN1) in Breast Cancer Tumor Progression
    Lidija Covic, Ph.D.
    New England Medical Center Hospitals, Inc.
    Tumor Cell Biology VI
    $300,000


    A Personalized Approach for the Treatment of Metastatic Breast Cancer
    Paul Hergenrother, Ph.D.
    The Board of Trustees of the University of Illinois at Urbana-Champaign
    Treatment
    $300,000


    Immunotherapeutic Synergy Between Chemotherapy and A Breast Cancer Vaccine
    Leisha Emens, M.D., Ph.D.
    Johns Hopkins University
    Tumor Cell Biology IV
    $300,000


    The Role of Therapy-Induced Autophagy and Apoptosis in Metastatic Breast Cancer Response
    Joan Bull, M.D.
    The University of Texas Health Science Center at Houston
    Detection/Diagnosis/Prognosis
    $300,000


    Collagen receptors as novel targets to lower the breast cancer risk associated with high mammographic density
    Wolfgang Vogel, PhD
    University of Toronto
    Tumor Cell Biology I
    $300,000


    Novel Natural Products for Breast Cancer Prevention and Treatment
    Hui (Hannah) Wang, MD, PhD
    The University of Alabama at Birmingham
    Treatment
    $300,000


    Combining vaccines and adoptive T cell transfer for breast cancer immunotherapy
    Philip Darcy, PhD, BSc
    Peter MacCallum Cancer Centre
    Tumor Cell Biology III
    $272,478


    A role for Pnck as a sensitizer to breast cancer therapeutics.
    Tushar Deb, Ph.D.
    Georgetown University
    Tumor Cell Biology VI
    $296,348


    Clinical Assessment of Cytochrome P450 (CYP)3A4 Induction by Tamoxifen: Potential Impact of Hormonal and Genetic Factors
    Pankaj Desai, Ph.D.
    University of Cincinnati
    Treatment
    $297,968


    Identifying the immunologic signature of early stage breast cancer using the neu-transgenic mouse to model the immunogenicity of human breast cancer
    Mary Disis, M.D.
    University of Washington
    Detection/Diagnosis/Prognosis
    $300,000


    Expression of estrogen receptor in breast cancer stem cells
    Gabriela Dontu, M.D., Ph.D.
    The Regents of the University of Michigan
    Detection/Diagnosis/Prognosis
    $300,000


    Reducing the Anti-apoptosis BRUCE Protein level Activates p53 Apoptosis Pathway and Sensitizes Breast Cancer Cells to Chemotherapy-induced Apoptosis
    Chunying Du, Ph.D.
    Stowers Institute for Medical Research
    Tumor Cell Biology III
    $300,000


    Breast Sound Speed: A Potential Predictor of Breast Cancer Risk
    Neb Duric, Ph.D.
    Barbara Ann Karmanos Cancer Institute
    Risk and Prevention, Epidemiology
    $299,941


    Circadian Control of Breast Cancer Development
    Carla Finkielstein, Ph.D.
    Virginia Polytechnic Institute and State University
    Tumor Cell Biology I
    $300,000


    The Role of Six1, and its target TGF beta R-I, in mediating breast cancer metastasis
    Heide Ford, B.S., M.S., Ph.D.
    Regents of the University of Colorado, University of Colorado at Denver and Health Sciences Center (UCDHSC) - Fitzsimons Campus
    Tumor Cell Biology II
    $300,000


    Targeting the Hedgehog Pathway in the Treatment of Breast Cancer
    Andra Frost, M.D.
    The University of Alabama at Birmingham
    Treatment
    $300,000


    Refined Prediction of Hormone Response
    Suzanne A. W. Fuqua, Ph.D
    Baylor College of Medicine
    Detection/Diagnosis/Prognosis
    $299,998


    Cyclin D1 as a marker of DCIS recurrence
    Doris Germain, PhD
    Mount Sinai School of Medicine
    Tumor Cell Biology V
    $299,877


    Defining the role of EpCAM in breast cancer invasion
    William Gillanders, M.D.
    Washington University in St. Louis
    Tumor Cell Biology V
    $300,000


    Detection of Early Stages of Breast Cancer Metastasis
    Dave Hoon, PhD
    John Wayne Cancer Institute
    Detection/Diagnosis/Prognosis
    $300,000


    Behavior Activation for Depressed Cancer Patients: Randomized Trial
    Derek Hopko, B.A., M.A., Ph.D.
    The University of Tennessee
    Treatment
    $296,267


    A Longitudinal Study of Alterations in Cognitive Function and Brain Metabolites among Women Receiving Chemotherapy for Primary Breast Cancer.
    Sadhna Kohli, Ph.D
    University of Rochester
    Psychosocial and Complementary Treatment Approache
    $300,000


    Signaling by ErbB/HER Family Receptors in Breast Cancer Cell Membranes
    John Koland, Ph.D.
    The University of Iowa
    Tumor Cell Biology II
    $300,000


    Human papilloma viruses and human breast cancer
    James Lawson, MD
    The University of New South Wales (UNSW)
    Risk, Prevention and Epidemiology
    $300,000


    Focus on Apical Polarity to Develop Breast Cancer Prevention Strategies
    Sophie Lelièvre, D.V.M., Ph.D.
    Purdue University
    Risk and Prevention, Epidemiology
    $300,000


    Accurate Breast Cancer Prognosis
    Jian Li, Ph.D.
    University of Florida
    Detection/Diagnosis/Prognosis
    $216,763


    Breast cancer: Molecular pathophysiology of paclitaxel-induced pain
    Wolfgang Liedtke, MD, PhD
    Duke University Medical Center
    Treatment
    $300,000


    Predicting Response to First-line Trastuzumab: eTag Analysis of Primary Breast Tumor Predictive Factors, and Metastatic Serum Biomarker Analysis
    Allan Lipton, M.D.
    The Pennsylvania State University College of Medicine
    Detection/Diagnosis/Prognosis
    $296,521


    Role of erbB3 in erbB2/neu-mediated Breast Cancer Development
    Bolin Liu, M.D.
    Regents of the University of Colorado, University of Colorado at Denver and Health Sciences Center (UCDHSC) - Fitzsimons Campus
    Tumor Cell Biology V
    $300,000


    The Role of Deleted in Breast Cancer 1 (DBC1) in SirT1 Regulation and Tumorigenesis
    zhenkun lou, Ph.D.
    Mayo Clinic Rochester
    Tumor Cell Biology I
    $295,509


    To Test a Culturally Sensitive Intervention among Chinese Breast Cancer Survivors Using Expressive Writing
    Qian Lu, Ph.D., M.D.
    The Regents of the University of California, Los Angeles
    Psychosocial and Complementary Treatment Approache
    $300,000


    Boosting Immunity to Metastatic Breast Cancer Using Targeted T Cells: A Phase II Clinical Trial
    Lawrence Lum, M.D.
    Wayne State University
    Treatment
    $300,000


    Multi-parameter molecular imaging of tumor susceptibility and early evaluation of therapeutic response
    Umar Mahmood, M.D., Ph.D.
    Massachusetts General Hospital (The General Hospital Corp.)
    Detection/Diagnosis/Prognosis
    $300,000


    Potential values of CAPC in early detection, treatment, and prevention of breast cancer invasion
    Yan-gao Man, M.D., Ph.D.
    American Registry of Pathology, Inc.
    Detection/Diagnosis/Prognosis
    $300,000


    Disintegrins as a Therapeutic and Imaging Agent for Metastatic Breast Cancer
    Francis Markland, Ph.D.
    USC/University of Southern California
    Detection/Diagnosis/Prognosis
    $300,000


    Glyolysis, IRS-2 and Metastatic Breast Cancer
    arthur mercurio, Ph.D.
    University of Massachusetts Medical School
    Tumor Cell Biology II
    $300,000


    Cell Cycle Inhibition Therapy:Stathmin As A Potential Therapeutic Target For Breast Cancer
    Sucharita Mistry, Ph.D
    Mount Sinai School of Medicine
    Tumor Cell Biology IV
    $300,000


    Thiamine starvation with thiaminase I for breast cancer therapy
    Jeffrey Moscow, M.D., Dartmouth Medical School, 1982
    University of Kentucky Research Foundation
    Tumor Cell Biology III
    $300,000


    Low-toxicity Retinoids to Prevent the Recurrence of ER- Breast Cancer
    Donald Muccio, Ph.D.
    The University of Alabama at Birmingham
    Risk, Prevention and Epidemiology
    $300,000


    Multivalent VRP-Based Immunotherapy for Breast Cancer
    Edward Nelson, M.D.
    The Regents of the University of California (Irvine)
    Tumor Cell Biology III
    $299,958


    A Novel Strategy to Find New Genetic Risk Factors for Breast Cancer
    Stanley Nelson, M.D.
    The Regents of the University of California, Los Angeles
    Detection/Diagnosis/Prognosis
    $289,216


    Adverse neurological consequences of breast cancer treatments: Causes and prevention
    Mark Noble, Ph.D.
    University of Rochester
    Psychosocial and Complementary Treatment Approache
    $299,940


    PTEN in the Breast Tumor Microenvironment
    Michael Ostrowski, PhD
    The Ohio State University Research Foundation
    Tumor Cell Biology II
    $300,000


    Targeting Langerhans cells for therapeutic vaccination in breast cancer
    Anna Palucka, M.D., Ph.D.
    Baylor Research Institute
    Treatment
    $299,643


    Anti-HER2/neu IgE for the Therapy of Breast Cancer
    Manuel Penichet, M.D., Ph.D.
    The Regents of the University of California, Los Angeles
    Treatment
    $299,988


    Regulating of MMP Secretion During the Invasion of Breast Cancer Cells
    Rytis Prekeris, Ph.D.
    Regents of the University of Colorado, University of Colorado at Denver and Health Sciences Center (UCDHSC) - Fitzsimons Campus
    Tumor Cell Biology II
    $299,993


    Epidermal growth factor receptor (EGFR)-related protein (ERRP), a novel pan-erbB inhibitor, is a potential targeted therapy for breast cancer.
    Arun Rishi, Ph.D.
    Wayne State University
    Tumor Cell Biology V
    $299,961


    Molecular Therapeutics of Breast-Associated Cancer Lymphedema
    Stanley Rockson, M.D.
    Stanford University
    Treatment
    $300,000


    A Phase I Trial of Continuous Low-Irradiance Photodynamic Therapy for Post-Mastectomy Chest Wall Recurrences of Breast Cancer
    Gary Rogers, MD
    New England Medical Center Hospitals, Inc.
    Treatment
    $264,233


    Epigenetic Silencing of BRCA-1 and Protective Effects of Dietary Components
    Donato Romagnolo, Ph.D.
    Arizona Board of Regents, University of Arizona
    Tumor Cell Biology VI
    $300,000


    Elucidating the contribution of bone to breast cancer metastasis using an engineered bone scaffold
    Michael Rosenblatt, M.D.
    TUFTS UNIVERSITY
    Tumor Cell Biology II
    $300,000


    Identification of breast cancer intravasation genes
    Thomas Rosol, D.V.M., Ph.D
    The Ohio State University Research Foundation
    Tumor Cell Biology VI
    $300,000


    Gene Profiling and in vivo Imaging in Characterizing the Metastatic Phenotype Regulated by the Type I IGF Receptor in Breast Cancer
    Deepali Sachdev, Ph.D.
    University of Minnesota - Twin Cities
    Tumor Cell Biology IV
    $300,000


    A Phase-II Pre-Clinical Study of Paclitaxel-Monoclonal Antibody Conjugates for Targeted Chemotherapy of Breast Cancer
    Ahmad Safavy, PhD
    The University of Alabama at Birmingham
    Treatment
    $300,000


    Role of Aryl Hydrocarbon Receptor and Cross Talk with Estrogen Receptor in Response of Breast Cancer Cells to the Novel Antitumor Agent Aminoflavone
    Edward Sausville, M.D.
    University of Maryland, Baltimore
    Treatment
    $300,000


    Vascular-targeted photodynamic therapy (VTP), imaging (VTI) and on-line prognosis of ductal carcinoma in situ (DCIS) using novel BCLs and BCL-RGDs.
    Avigdor Scherz, Ph.D.
    Weizmann Institute of Science
    Detection/Diagnosis/Prognosis
    $300,000


    Targeting AlphaVBeta3 Integrin and Src to Alleviate Breast Cancer Progression Stimulated by TGF-beta
    William Schiemann, Ph.D.
    Regents of the University of Colorado, University of Colorado at Denver and Health Sciences Center (UCDHSC) - Fitzsimons Campus
    Tumor Cell Biology II
    $300,000


    The Role of Beta1 and Beta4 Integrins in Endocrine and Anti-HER Therapy Resistance in Breast Cancer
    Rachel Schiff, Ph. D.
    Baylor College of Medicine
    Tumor Cell Biology III
    $299,926


    Diagnostic and Therapeutic Strategies Targeting the c-Myc Oncoprotein
    Rosalie Sears, Ph.D.
    Oregon Health & Science University
    Tumor Cell Biology I
    $299,983


    Development of Small Molecule Activator of Death Receptor for Breast Cancer Therapy
    Sharmila Shankar, Ph.D.
    The University of Texas Health Center at Tyler
    Tumor Cell Biology III
    $300,000


    The MCM2-7 complex and breast cancer
    Naoko Shima, Ph.D.
    University of Minnesota - Twin Cities
    Tumor Cell Biology V
    $300,000


    Aged Stroma in Breast Tumorigenesis: Development of an In Vivo Model
    Sheila Stewart, Ph.D.
    Washington University in St. Louis
    Tumor Cell Biology II
    $300,000


    Design, Synthesis and Evaluation of XIAP inhibitors as a Novel Therapy for the Treatment of Human Breast Cancer
    Haiying Sun, Ph.D.
    The Regents of the University of Michigan
    Treatment
    $300,000


    Evaluation of immune response to HERV antigens as vaccines for breast cancer
    Feng Wang-Johanning, M.D. and Ph.D.
    University of Texas M.D. Anderson Cancer Center
    Treatment
    $299,290


    Tumor-Targeted rVSV-F Vectors for Treatment of Metastatic Breast Cancer
    Savio Woo, Ph.D.
    Mount Sinai School of Medicine
    Treatment
    $300,000


    Regulation of SRC-3/AIB1 Function by Akt/PKB Kinase Signaling Pathway and the Potential Role in Endocrine Therapy Resistance
    Ray-Chang Wu, Ph.D.
    Baylor College of Medicine
    Tumor Cell Biology I
    $300,000


    BRCA1 Regulates AKT1 Activity in Breast Cancer
    Qin Yang, Ph.D., M.D.
    Washington University in St. Louis
    Tumor Cell Biology V
    $300,000


    Activating innate immunity to fight breast cancer
    Jinghua Yang, Ph.D.
    Boston VA Research Institute, Inc.
    Risk, Prevention and Epidemiology
    $298,932


    Mechanisms Of IRF-1 Induced Apoptosis In Breast Cancer
    John Yim, MD
    University of Pittsburgh
    Tumor Cell Biology III
    $300,000


    Discovery of novel ligands for breast cancer-related microRNA precursors
    Yohei Yokobayashi, Ph.D.
    The Regents of the University of California (University of California Davis)
    Tumor Cell Biology V
    $300,000


    Serum Epigenetic Markers and the Early Detection of Breast Cancer
    Anne Zeleniuch-Jacquotte, M.D.
    New York University School of Medicine
    Detection/Diagnosis/Prognosis
    $186,724


    Breast tumor exosomal Jak3BP inhibits myeloid cell differentiation
    huang-ge zhang, PhD
    The University of Alabama at Birmingham
    Tumor Cell Biology III
    $300,000


    Molecular Biomarkers to Predict Local Recurrence of Breast Cancer
    Yun-Ling Zheng, Ph.D.
    Georgetown University
    Risk, Prevention and Epidemiology
    $300,000



    * Pending executed agreement